The latest series of review articles in the Blood Journal provides a comprehensive overview of the current landscape of myelodysplastic syndromes (MDS), highlighting recent advances in biological and clinical science.
In the introduction to the series, Bob Löwenberg, M.D., Ph.D., discusses advances in the diagnostic process and treatment beyond traditional approaches to care.
Articles in the series include:
- State-of-the-art approaches to MDS treatment and upcoming therapeutic options
- A focus on “precision diagnostics” and the diagnostic issues of defining MDS relative to other “boundary” conditions
- An exploration of the marrow niche and underlying mechanisms initiating or supporting the development of MDS
- An examination of the inflammatory and innate immune signals that may act as strong pathogenetic MDS drivers
- An analysis of molecular drivers and patterns of disease evolution, and their correlation with clinical disease phenotypes
- Significant genomic and epigenomic insights into the origin of juvenile chronic myelomonocytic leukemia
- The ever-growing area of clinically relevant hereditary MDS knowledge